Allurion Technologies, Inc. (ALUR): R&D Expense
$7.57M
Year ended 2025-12-31
$5.86M
Trailing 12 months to 2026-03-31
-23.6%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.57M | -56.4% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $17.37M | -37.3% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $27.69M | +63.2% | 2025-08-28, From 2023-01-01 |
| 2022-12-31 | $16.97M | n/a | 2025-08-28, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $7.57M | -56.4% |
| Biotricity Inc. (BTCY) | 2026-03-31 | $2.76M | +28.2% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $20.60M | +21.4% |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $100.0K | 0.0% |
| Nephros Inc (NEPH) | 2025-12-31 | $1.34M | +47.8% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $2.27M | +25.2% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $2.0K | -97.4% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $13.79M | -43.0% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $20.13M | +226.0% |
Compare ALUR, BTCY, PROF, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗